Evaluation of MHP 3.0 in Two Clinical Settings
Pilot MHP 3.0 in Two Clinical Settings to Evaluate Acceptability and Feasibility of MHP
1 other identifier
interventional
150
1 country
1
Brief Summary
The purpose of this study is to assess the acceptability and feasibility of the use of MyHealthyPregnancy (MHP) 3.0 in clinical practice over a 1 year period of time. The investigators will pilot MHP 3.0 (Spanish and English language options) at practice sites at the Obstetrix Medical Group of Houston, Texas and the UPMC (University of Pittsburgh Medical Center) Healthcare System. Patient and care team feedback will be assessed throughout this study. Patients at Obstetrix Medical Group of Houston will be assessed using 4 short acceptability and feasibility surveys administered by the Naima Health team using a link for an online survey during the study term: at baseline, week 14-18, week 24-28, and week 34-36. A subset of participants at UPMC will also be asked to complete user surveys.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2022
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 16, 2021
CompletedFirst Posted
Study publicly available on registry
April 28, 2021
CompletedStudy Start
First participant enrolled
June 20, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 31, 2023
CompletedAugust 12, 2022
August 1, 2022
9 months
April 16, 2021
August 9, 2022
Conditions
Outcome Measures
Primary Outcomes (4)
Change in number of patients that screen positive
Measured by the number of patients who screen positive for depression and/or intimate partner violence through the app compared to the number of patients who have screened positive for depression and/or intimate partner violence historically through routine prenatal care. Higher numbers mean better outcomes.
8 months
Percentage of questionnaires completed
Measured by calculating the percentage of questionnaires completed by each user from the total administered through the MHP app. Values would range from 0% to 100%. Higher numbers mean better outcomes.
8 months
Usability Questionnaire
This questionnaire will assess subjective opinions about the usability of MHP. This questionnaire includes 7 questions that will use a Likert scale anchored from 1/strongly disagree to 5/strongly agree. The minimum value is 7 and the maximum value of 35. Higher numbers mean better outcomes.
8 months
Acceptability Questionnaire
This questionnaire will assess subjective opinions about the acceptability of the content in MHP. This questionnaire includes 6 questions that will use a Likert scale anchored from 1/strongly disagree to 5/strongly agree. The minimum value is 6 and the maximum value of 30. Higher numbers mean better outcomes.
8 months
Study Arms (1)
MHP Users
EXPERIMENTALA subset of the population within the clinical setting will be requested to participate in this pilot while the rest of the population will receive standard of care.
Interventions
MyHealthyPregnancy app (MHP 3.0) is a mHealth app specifically focused on detection and referral for depression and IPV (Intimate Partner Violence) risk, in addition to its other pregnancy risk detection and support features.
Eligibility Criteria
You may qualify if:
- Is at least 18 years of age
- Currently pregnant and in gestational week 12 or less
- Is under the care of a participating provider/clinic
- Owns a smartphone
- Spanish or English native speaker
You may not qualify if:
- Under 18 years of age
- Not pregnant at time of enrollment
- Is pregnant but over 12 weeks of gestational age
- Provider is not part of the study
- Does not own a smartphone
- Native language is not Spanish or English
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Naima Health LLClead
- University of Pittsburghcollaborator
- Obstetrix Medical Groupcollaborator
Study Sites (1)
Obstetrix Medical Center Houston
Houston, Texas, 77477, United States
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SCREENING
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 16, 2021
First Posted
April 28, 2021
Study Start
June 20, 2022
Primary Completion
March 31, 2023
Study Completion
March 31, 2023
Last Updated
August 12, 2022
Record last verified: 2022-08
Data Sharing
- IPD Sharing
- Will not share